Pricing Log in Create free account

KARDIGAN INC (KARD) vs Urogen Pharma (URGN)

KARDIGAN INC and Urogen Pharma are both Biotechnology companies. KARDIGAN INC and Urogen Pharma are of similar size ($1.3B and $1.3B). KARDIGAN INC has the higher net margin (0.00% vs −26.3%) and the lower return on invested capital (−908.8% vs 0.00%). Across the 12 metrics below, Urogen Pharma leads on 7 and KARDIGAN INC on 5.

Valuation

Metric KARD URGN Biotechnology median
P/E n/m n/m 10.60
P/S n/m 5.01 9.40
P/B 0.63 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.82 n/m 0.66
EV/Sales n/m 5.41 9.02
Earnings yield (95.11%) (5.32%) (32.88%)
Free cash flow yield (43.18%) (10.53%) (23.13%)

Profitability

Metric KARD URGN Biotechnology median
Gross margin — 91.41% 68.51%
Operating margin 0.00% (12.36%) 0.00%
Net margin 0.00% (26.27%) 0.00%
Free cash flow margin 0.00% (52.77%) 0.00%
Return on equity 0.00% 54.65% (51.96%)
Return on assets 0.00% (28.78%) (46.06%)
Return on invested capital (908.80%) 0.00% 0.00%

Growth

Metric KARD URGN Biotechnology median
Revenue growth (TTM) — 159.29% 6.76%
EPS growth (last fiscal year) (68.79%) (7.77%) 29.88%
Revenue growth, 5-year CAGR — 56.22% 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric KARD URGN Biotechnology median
Debt to equity 0.00 (1.53) 0.00
Current ratio 8.72 3.40 4.97
Net debt to EBITDA 1.70 0.00 1.01

Dividend

Metric KARD URGN Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric KARD URGN Biotechnology median
Market cap 1.30b 1.26b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack